Risk factor
Very high price volatility
Profitability factor
Undervalued vs peers
About
Bod Science Limited operates as a cannabis focused drug development and product innovation company in Australia, the United Kingdom, the European Union, and the United States. The company operates through three segments: Medical, Over The Counter (OTC) Cannabidiol/Hemp, and OTC Herbals. It engages in the development and manufacture of cannabidiol and hemp products for consumers; and development and distribution of therapeutics medicinal cannabis products for medical markets. The company provides Flexofytol, an anti-inflammatory derived from a scientifically validated and clinically trialed turmeric extract that helps in improving joint health, limiting the ageing of cartilage, and reducing inflammation caused by mild arthritis; and Sedistress, a passion flower extract that reduces the symptoms of stress, anxiety, and insomnia. The company was formerly known as Bod Australia Limited and changed its name to Bod Science Limited in December 2022. Bod Science Limited was incorporated in 2014 and is based in Double Bay, Australia.
Company Valuation
Considering past and projected metrics, the stock is 'cheaper' than its peers. Specifically, the stock is fairly valued on P/E, underpriced on P/FC.